Article(id=1207416367888830837, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1207416365246419268, articleNumber=null, orderNo=null, doi=10.11855/j.issn.0577-7402.2022.09.0947, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1630944000000, receivedDateStr=2021-09-07, revisedDate=null, revisedDateStr=null, acceptedDate=1634659200000, acceptedDateStr=2021-10-20, onlineDate=1765800094816, onlineDateStr=2025-12-15, pubDate=1664294400000, pubDateStr=2022-09-28, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1765800094816, onlineIssueDateStr=2025-12-15, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1765800094816, creator=13701087609, updateTime=1765800094816, updator=13701087609, issue=Issue{id=1207416365246419268, tenantId=1146029695717560320, journalId=1189873630562394117, year='2022', volume='47', issue='9', pageStart='851', pageEnd='956', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1765800094186, creator=13701087609, updateTime=1765800167087, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1207416671069904914, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1207416365246419268, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1207416671069904915, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1207416365246419268, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=947, endPage=953, ext={EN=ArticleExt(id=1207416368346009997, articleId=1207416367888830837, tenantId=1146029695717560320, journalId=1189873630562394117, language=EN, title=Research advances on vonoprazan for eradication of Helicobacter pylori, columnId=1190243275882729994, journalTitle=Medical Journal of Chinese People’s Liberation Army, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Helicobacter pylori (Hp) infection is a common chronic bacterial infection in humans, which is significantly associated with a variety of gastrointestinal diseases. Traditionally, Hp eradication is based on one type of proton pump inhibitors(PPIs) combined with two types of antibiotics. PPIs could increase the pH value in the stomach to strengthen the bactericidal or antibacterial effects of antibiotics. Vonoprazan is a new drug with a stronger acid-suppressing effect compared to PPIs. Vonoprazan-based regimens are not inferior to PPIs-based regimens for eradicating Hp and are well tolerated. This article aims to summarize the effects of vonoprazan-based treatment strategy for Hp eradication, including vonoprazan-based first-line, second-line, and third-line regimens, vonoprazan-based regimens on penicillin-allergic and clarithromycin-resistant patients, vonoprazan-based dual and first-line triple regimens, and 10-14 d vonoprazan-based regimens.

, correspAuthors=Xing-Shun Qi, authorNote=null, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Wen-Tao Xu, Xiang-Bo Xu, Tian-Shu Ren, Xing-Shun Qi), CN=ArticleExt(id=1207416370149560754, articleId=1207416367888830837, tenantId=1146029695717560320, journalId=1189873630562394117, language=CN, title=伏诺拉生在幽门螺杆菌根除治疗中的作用研究进展, columnId=1190243276029530637, journalTitle=解放军医学杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

幽门螺杆菌(Hp)感染是人类常见的慢性细菌感染，与多种胃肠道疾病相关。传统的Hp根除方案为质子泵抑制剂(PPIs)联合2种抗生素，其中PPIs通过提高胃内pH值加强抗菌素的杀菌或抑菌作用。伏诺拉生是一种新型抑酸药物，其抑酸作用强于PPIs。基于伏诺拉生方案根除Hp的效果不劣于PPIs，且耐受性良好。本文从伏诺拉生一线、二线、三线方案的Hp根除效果，伏诺拉生方案对青霉素过敏患者、克拉霉素耐药患者的Hp根除效果，伏诺拉生双联方案及一线三联方案根除Hp的效果，以及10~14 d伏诺拉生方案根除Hp的效果等方面进行综述，以评估伏诺拉生在Hp根除治疗中的临床应用价值。

, correspAuthors=祁兴顺, authorNote=null, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Opdyft9N9kGbdGEWNXSWiw==, magXml=dCo2DJ5KBy5bbt07f3WNyg==, pdfUrl=null, pdf=+aCG3cjndZF0EXN4NBOEfA==, pdfFileSize=1277876, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=6QF99VI8Tw2AqB+roMVTzQ==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=Tobqh1mB1Mk/MDJ8D3n7Gw==, mapNumber=null, authorCompany=null, fund=null, authors=, authorsList=许文涛, 许向波, 任天舒, 祁兴顺)}, authors=[Author(id=1207416370711597524, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1207416370799677916, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416370711597524, language=EN, stringName=Wen-Tao Xu, firstName=Wen-Tao, middleName=null, lastName=Xu, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China
²Postgraduate College, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1207416370912924130, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416370711597524, language=CN, stringName=许文涛, firstName=文涛, middleName=null, lastName=许, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹北部战区总医院消化内科，辽宁沈阳 110840
²沈阳药科大学研究生院，辽宁沈阳 110016, bio={"content":"

许文涛，硕士研究生，主要从事消化系统疾病方面的研究

"}, bioImg=null, bioContent=

许文涛，硕士研究生，主要从事消化系统疾病方面的研究

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1207416370388636093, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=1, ext=[AuthorCompanyExt(id=1207416370413801918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370430579136, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北部战区总医院消化内科，辽宁沈阳 110840)]), AuthorCompany(id=1207416370510270918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=2, ext=[AuthorCompanyExt(id=1207416370518659528, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Postgraduate College, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China), AuthorCompanyExt(id=1207416370531242442, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²沈阳药科大学研究生院，辽宁沈阳 110016)])]), Author(id=1207416371009393126, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1207416371126833646, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371009393126, language=EN, stringName=Xiang-Bo Xu, firstName=Xiang-Bo, middleName=null, lastName=Xu, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China
²Postgraduate College, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1207416371282022896, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371009393126, language=CN, stringName=许向波, firstName=向波, middleName=null, lastName=许, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, 2}, address=¹北部战区总医院消化内科，辽宁沈阳 110840
²沈阳药科大学研究生院，辽宁沈阳 110016, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1207416370388636093, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=1, ext=[AuthorCompanyExt(id=1207416370413801918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370430579136, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北部战区总医院消化内科，辽宁沈阳 110840)]), AuthorCompany(id=1207416370510270918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=2, ext=[AuthorCompanyExt(id=1207416370518659528, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Postgraduate College, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China), AuthorCompanyExt(id=1207416370531242442, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²沈阳药科大学研究生院，辽宁沈阳 110016)])]), Author(id=1207416371428823541, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1207416371512709627, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371428823541, language=EN, stringName=Tian-Shu Ren, firstName=Tian-Shu, middleName=null, lastName=Ren, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=³, address=³Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1207416371613372930, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371428823541, language=CN, stringName=任天舒, firstName=天舒, middleName=null, lastName=任, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=³, address=³北部战区总医院药剂科，辽宁沈阳 110840, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1207416370627711440, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=3, ext=[AuthorCompanyExt(id=1207416370631905742, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370627711440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=³Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370636100047, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370627711440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=³北部战区总医院药剂科，辽宁沈阳 110840)])]), Author(id=1207416371701453321, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xingshunqi@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1207416371814699534, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371701453321, language=EN, stringName=Xing-Shun Qi, firstName=Xing-Shun, middleName=null, lastName=Qi, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, *}, address=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1207416371898585618, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, authorId=1207416371701453321, language=CN, stringName=祁兴顺, firstName=兴顺, middleName=null, lastName=祁, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^{1, *}, address=¹北部战区总医院消化内科，辽宁沈阳 110840, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1207416370388636093, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=1, ext=[AuthorCompanyExt(id=1207416370413801918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370430579136, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北部战区总医院消化内科，辽宁沈阳 110840)])])], keywords=[Keyword(id=1207416372028609045, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, orderNo=1, keyword=vonoprazan), Keyword(id=1207416372112495129, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, orderNo=2, keyword=Helicobacter pylori), Keyword(id=1207416372183798303, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, orderNo=3, keyword=proton pump inhibitors), Keyword(id=1207416372292850213, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, orderNo=1, keyword=伏诺拉生), Keyword(id=1207416372376736297, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, orderNo=2, keyword=幽门螺杆菌), Keyword(id=1207416372481593901, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, orderNo=3, keyword=质子泵抑制剂)], refs=[Reference(id=1207416374494859857, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=153, issue=2, pageStart=420, pageEnd=429, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=Hooi JK Y, Lai WY, Ng WK, journalName=Gastroenterology, refType=null, unstructuredReference=Hooi JK Y, Lai WY, Ng WK et al. Global prevalence of Helicobacter pylori infection: Systematic review and Meta-analysis[J]. Gastroenterology, 2017, 153(2): 420-429., articleTitle=Global prevalence of Helicobacter pylori infection: Systematic review and Meta-analysis, refAbstract=null), Reference(id=1207416374587134552, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=161, issue=2, pageStart=495, pageEnd=507.e4, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=Rokkas T, Gisbert JP, Malfertheiner P, journalName=Gastroenterology, refType=null, unstructuredReference=Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: A network Meta-analysis[J]. Gastroenterology, 2021, 161(2): 495-507.e4., articleTitle=Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: A network Meta-analysis, refAbstract=null), Reference(id=1207416374691992155, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=7, issue=null, pageStart=CD005583, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=Ford AC, Yuan Y, Forman D, journalName=Cochrane Database Syst Rev, refType=null, unstructuredReference=Ford AC, Yuan Y, Forman D, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia[J]. Cochrane Database Syst Rev, 2020, 7: CD005583., articleTitle=Helicobacter pylori eradication for the prevention of gastric neoplasia, refAbstract=null), Reference(id=1207416374805238367, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2015, volume=64, issue=9, pageStart=1353, pageEnd=1367, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=Sugano K, Tack J, Kuipers EJ, journalName=Gut, refType=null, unstructuredReference=Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64(9):1353-1367., articleTitle=Kyoto global consensus report on Helicobacter pylori gastritis, refAbstract=null), Reference(id=1207416374910095972, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2016, volume=43, issue=4, pageStart=514, pageEnd=533, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=Thung I, Aramin H, Vavinskaya V, journalName=Aliment Pharmacol Ther, refType=null, unstructuredReference=Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance[J]. Aliment Pharmacol Ther, 2016, 43(4): 514-533., articleTitle=Review article: The global emergence of Helicobacter pylori antibiotic resistance, refAbstract=null), Reference(id=1207416375073673833, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=25, issue=Suppl 1, pageStart=e12743, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=O'Connor A, Furuta T, Gisbert JP, journalName=Helicobacter, refType=null, unstructuredReference=O'Connor A, Furuta T, Gisbert JP, et al. Review-Treatment of Helicobacter pylori infection 2020[J]. Helicobacter, 2020, 25(Suppl 1): e12743., articleTitle=Review-Treatment of Helicobacter pylori infection 2020, refAbstract=null), Reference(id=1207416375144977003, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2016, volume=39, issue=1, pageStart=14, pageEnd=23, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=Kao CY, Sheu BS, Wu JJ, journalName=Biomed J, refType=null, unstructuredReference=Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis[J]. Biomed J, 2016, 39(1): 14-23., articleTitle=Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis, refAbstract=null), Reference(id=1207416375241446000, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=1998, volume=43, issue=Suppl 1, pageStart=S56, pageEnd=60, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=Scott D, Weeks D, Melchers K, journalName=Gut, refType=null, unstructuredReference=Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori[J]. Gut, 1998, 43 (Suppl 1): S56-60., articleTitle=The life and death of Helicobacter pylori, refAbstract=null), Reference(id=1207416375333720694, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=53, issue=7, pageStart=794, pageEnd=809, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=Abdel-Aziz Y, Metz DC, Howden CW, journalName=Aliment Pharmacol Ther, refType=null, unstructuredReference=Abdel-Aziz Y, Metz DC, Howden CW. Review article:Potassium-competitive acid blockers for the treatment of acid-related disorders[J]. Aliment Pharmacol Ther, 2021, 53(7): 794-809., articleTitle=Review article:Potassium-competitive acid blockers for the treatment of acid-related disorders, refAbstract=null), Reference(id=1207416375421801080, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2016, volume=168, issue=null, pageStart=12, pageEnd=22, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=Inatomi N, Matsukawa J, Sakurai Y, journalName=Pharmacol Ther, refType=null, unstructuredReference=Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases[J]. Pharmacol Ther, 2016, 168: 12-22., articleTitle=Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases, refAbstract=null), Reference(id=1207416375522464379, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2016, volume=43, issue=10, pageStart=1048, pageEnd=1059, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=Kagami T, Sahara S, Ichikawa H, journalName=Aliment Pharmacol Ther, refType=null, unstructuredReference=Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype[J]. Aliment Pharmacol Ther, 2016, 43(10):1048-1059., articleTitle=Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype, refAbstract=null), Reference(id=1207416375585378944, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2015, volume=42, issue=6, pageStart=719, pageEnd=730, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=Sakurai Y, Mori Y, Okamoto H, journalName=Aliment Pharmacol Ther, refType=null, unstructuredReference=Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--A randomised open-label cross-over study[J]. Aliment Pharmacol Ther, 2015, 42(6): 719-730., articleTitle=Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--A randomised open-label cross-over study, refAbstract=null), Reference(id=1207416375669265024, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=22, issue=6, pageStart=e12438, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=Dong SQ, Singh TP, Wei X, journalName=Helicobacter, refType=null, unstructuredReference=Dong SQ, Singh TP, Wei X, et al. Review: A Japanese population-based Meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?[J]. Helicobacter, 2017, 22(6): e12438., articleTitle=Review: A Japanese population-based Meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?, refAbstract=null), Reference(id=1207416375769928323, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=66, issue=4, pageStart=752, pageEnd=753, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=Katayama Y, Toyoda K, Kusano Y, journalName=Gut, refType=null, unstructuredReference=Katayama Y, Toyoda K, Kusano Y, et al. Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based fi rst-line treatment failed[J]. Gut, 2017, 66(4): 752-753., articleTitle=Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based fi rst-line treatment failed, refAbstract=null), Reference(id=1207416375849620104, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2016, volume=65, issue=9, pageStart=1439, pageEnd=1446, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=Murakami K, Sakurai Y, Shiino M, journalName=Gut, refType=null, unstructuredReference=Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication:A phase III, randomised, double-blind study[J]. Gut, 2016, 65(9): 1439-1446., articleTitle=Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication:A phase III, randomised, double-blind study, refAbstract=null), Reference(id=1207416375937700492, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=2017, issue=null, pageStart=4385161, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=Maruyama M, Tanaka N, Kubota D, journalName=Can J Gastroenterol Hepatol, refType=null, unstructuredReference=Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: A randomized controlled trial[J]. Can J Gastroenterol Hepatol, 2017, 2017: 4385161., articleTitle=Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: A randomized controlled trial, refAbstract=null), Reference(id=1207416376029975180, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2018, volume=23, issue=2, pageStart=e12456, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=Sue S, Ogushi M, Arima I, journalName=Helicobacter, refType=null, unstructuredReference=Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial[J]. Helicobacter, 2018, 23(2): e12456., articleTitle=Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial, refAbstract=null), Reference(id=1207416376139027086, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2018, volume=97, issue=3, pageStart=212, pageEnd=218, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=Ozaki H, Harada S, Takeuchi T, journalName=Digestion, refType=null, unstructuredReference=Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: A large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy[J]. Digestion, 2018, 97(3): 212-218., articleTitle=Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: A large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy, refAbstract=null), Reference(id=1207416376222913169, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=56, issue=11, pageStart=1277, pageEnd=1285, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=Sue S, Kuwashima H, Iwata Y, journalName=Intern Med, refType=null, unstructuredReference=Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin:A prospective multi-center cohort study on Helicobacter pylori eradication[J]. Intern Med, 2017, 56(11): 1277-1285., articleTitle=The superiority of vonoprazan-based first-line triple therapy with clarithromycin:A prospective multi-center cohort study on Helicobacter pylori eradication, refAbstract=null), Reference(id=1207416376323576466, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2019, volume=11, issue=1, pageStart=116, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=Saito Y, Konno K, Sato M, journalName=Cancers (Basel), refType=null, unstructuredReference=Saito Y, Konno K, Sato M, et al. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori[J]. Cancers (Basel), 2019, 11(1): 116., articleTitle=Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori, refAbstract=null), Reference(id=1207416376411656854, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2019, volume=34, issue=4, pageStart=686, pageEnd=692, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=Sue S, Shibata W, Sasaki T, journalName=J Gastroenterol Hepatol, refType=null, unstructuredReference=Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori[J]. J Gastroenterol Hepatol, 2019, 34(4): 686-692., articleTitle=Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori, refAbstract=null), Reference(id=1207416376533291672, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=2017, issue=null, pageStart=2019802, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=Sue S, Suzuki N, Shibata W, journalName=Gastroenterol Res Pract, refType=null, unstructuredReference=Sue S, Suzuki N, Shibata W, et al. First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin[J]. Gastroenterol Res Pract, 2017, 2017: 2019802., articleTitle=First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin, refAbstract=null), Reference(id=1207416376688480925, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=55, issue=11, pageStart=1054, pageEnd=1061, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=Okubo H, Akiyama J, Kobayakawa M, journalName=J Gastroenterol, refType=null, unstructuredReference=Okubo H, Akiyama J, Kobayakawa M, et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility[J]. J Gastroenterol, 2020, 55(11): 1054-1061., articleTitle=Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility, refAbstract=null), Reference(id=1207416376772367007, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=69, issue=6, pageStart=1019, pageEnd=1026, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=Suzuki S, Gotoda T, Kusano C, journalName=Gut, refType=null, unstructuredReference=Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicentre randomised trial in Japan[J]. Gut, 2020, 69(6): 1019-1026., articleTitle=Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicentre randomised trial in Japan, refAbstract=null), Reference(id=1207416376839475873, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=55, issue=10, pageStart=969, pageEnd=976, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=Gotoda T, Kusano C, Suzuki S, journalName=J Gastroenterol, refType=null, unstructuredReference=Gotoda T, Kusano C, Suzuki S, et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan[J]. J Gastroenterol, 2020, 55(10): 969-976., articleTitle=Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan, refAbstract=null), Reference(id=1207416376994665125, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=101, issue=6, pageStart=743, pageEnd=751, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=Furuta T, Yamade M, Kagami T, journalName=Digestion, refType=null, unstructuredReference=Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori[J]. Digestion, 2020, 101(6): 743-751., articleTitle=Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori, refAbstract=null), Reference(id=1207416377091134117, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2020, volume=25, issue=5, pageStart=e12719, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=Hirata Y, Yamada A, Niikura R, journalName=Helicobacter, refType=null, unstructuredReference=Hirata Y, Yamada A, Niikura R, et al. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study[J]. Helicobacter, 2020, 25(5): e12719., articleTitle=Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study, refAbstract=null), Reference(id=1207416377170825895, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=Huh KY, Chung H, Kim YK, journalName=Br J Clin Pharmacol, refType=null, unstructuredReference=Huh KY, Chung H, Kim YK, et al. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication[J]. Br J Clin Pharmacol, 2021. doi: 10.1111/bcp.14934., articleTitle=Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication, refAbstract=null), Reference(id=1207416377254711978, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=22, issue=3, pageStart=e12374, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=Ono S, Kato M, Nakagawa S, journalName=Helicobacter, refType=null, unstructuredReference=Ono S, Kato M, Nakagawa S, et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin[J]. Helicobacter, 2017, 22(3): e12374., articleTitle=Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin, refAbstract=null), Reference(id=1207416377346986668, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2019, volume=2019, issue=null, pageStart=9781212, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=Lyu QJ, Pu QH, Zhong XF, journalName=Biomed Res Int, refType=null, unstructuredReference=Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A Meta-analysis of randomized clinical trials[J]. Biomed Res Int, 2019, 2019:9781212., articleTitle=Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A Meta-analysis of randomized clinical trials, refAbstract=null), Reference(id=1207416377409901230, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=46, issue=2, pageStart=106, pageEnd=114, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=Jung YS, Kim EH, Park CH, journalName=Aliment Pharmacol Ther, refType=null, unstructuredReference=Jung YS, Kim EH, Park CH. Systematic review with Meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication[J]. Aliment Pharmacol Ther, 2017, 46(2): 106-114., articleTitle=Systematic review with Meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication, refAbstract=null), Reference(id=1207416378609472177, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=56, issue=4, pageStart=303, pageEnd=322, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=Kamada T, Satoh K, Itoh T, journalName=J Gastroenterol, refType=null, unstructuredReference=Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020[J]. J Gastroenterol, 2021, 56(4): 303-322., articleTitle=Evidence-based clinical practice guidelines for peptic ulcer disease 2020, refAbstract=null), Reference(id=1207416378710135476, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=102, issue=3, pageStart=319, pageEnd=325, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=Shinozaki S, Kobayashi Y, Osawa H, journalName=Digestion, refType=null, unstructuredReference=Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and Meta-analysis[J]. Digestion, 2021, 102(3): 319-325., articleTitle=Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and Meta-analysis, refAbstract=null), Reference(id=1207416378802410166, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2018, volume=23, issue=4, pageStart=e12495, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=Li M, Oshima T, Horikawa T, journalName=Helicobacter, refType=null, unstructuredReference=Li M, Oshima T, Horikawa T, et al. Systematic review with Meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori[J]. Helicobacter, 2018, 23(4): e12495., articleTitle=Systematic review with Meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori, refAbstract=null), Reference(id=1207416378886296249, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=116, issue=1, pageStart=1, pageEnd=3, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=Howden CW, Graham DY, journalName=Am J Gastroenterol, refType=null, unstructuredReference=Howden CW, Graham DY. Recent developments pertaining to H.pylori infection[J]. Am J Gastroenterol, 2021, 116(1): 1-3., articleTitle=Recent developments pertaining to H.pylori infection, refAbstract=null), Reference(id=1207416378970182329, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2021, volume=26, issue=5, pageStart=e12830, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=Gunaratne AW, Hamblin H, Clancy A, journalName=Helicobacter, refType=null, unstructuredReference=Gunaratne AW, Hamblin H, Clancy A, et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-exploratory study[J]. Helicobacter, 2021, 26(5): e12830., articleTitle=Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-exploratory study, refAbstract=null), Reference(id=1207416379066651325, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=22, issue=6, pageStart=346, pageEnd=360, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=Chinese Study Group on Helicobacter pylori and Peptic Ulcer, Chinese Society of Gastroenterology, Liu WZ, journalName=Chin J Gastroenterol, refType=null, unstructuredReference=Chinese Study Group on Helicobacter pylori and Peptic Ulcer, Chinese Society of Gastroenterology, Liu WZ, et al. The fifth Chinese national consensus report on management of Helicobacter pylori infection[J]. Chin J Gastroenterol, 2017, 22(6): 346-360., articleTitle=The fifth Chinese national consensus report on management of Helicobacter pylori infection, refAbstract=null), Reference(id=1207416379209257663, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, doi=null, pmid=null, pmcid=null, year=2017, volume=22, issue=6, pageStart=346, pageEnd=360, url=null, language=null, rfNumber=[37], rfOrder=37, authorNames=中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 全国幽门螺杆菌研究协作组, 刘文忠, journalName=胃肠病学, refType=null, unstructuredReference=[中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 全国幽门螺杆菌研究协作组, 刘文忠, 等.第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.], articleTitle=第五次全国幽门螺杆菌感染处理共识报告, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1207416370388636093, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=1, ext=[AuthorCompanyExt(id=1207416370413801918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370430579136, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370388636093, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北部战区总医院消化内科，辽宁沈阳 110840)]), AuthorCompany(id=1207416370510270918, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=2, ext=[AuthorCompanyExt(id=1207416370518659528, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Postgraduate College, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China), AuthorCompanyExt(id=1207416370531242442, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370510270918, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²沈阳药科大学研究生院，辽宁沈阳 110016)]), AuthorCompany(id=1207416370627711440, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, xref=3, ext=[AuthorCompanyExt(id=1207416370631905742, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370627711440, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=³Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China), AuthorCompanyExt(id=1207416370636100047, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, companyId=1207416370627711440, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=³北部战区总医院药剂科，辽宁沈阳 110840)])], figs=[ArticleFig(id=1207416372640977458, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, label=Fig. 1, caption=Comparison on the 7 d eradication rate of Helicobacter pylori by vonoprazan-based and PPIs-based triple regimens, figureFileSmall=CaBDHLmYn7+k4I0JcZHg9Q==, figureFileBig=6QF99VI8Tw2AqB+roMVTzQ==, tableContent=null), ArticleFig(id=1207416372720669240, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, label=图1, caption=伏诺拉生方案与PPIs三联方案的Hp 7 d根除率比较

PPIs. 质子泵抑制剂；Hp. 幽门螺杆菌；ITT. 意向性分析；PP. 遵循研究方案分析

, figureFileSmall=CaBDHLmYn7+k4I0JcZHg9Q==, figureFileBig=6QF99VI8Tw2AqB+roMVTzQ==, tableContent=null), ArticleFig(id=1207416372947161666, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, label=Fig. 2, caption=Comparison on the eradication rate of Helicobacter pylori between dual and triple vonoprazan-based regimens, figureFileSmall=9BguXX4TNRAFy+n+ZQZ5Yw==, figureFileBig=8ZFR7VjiCved1jbOtzKFHw==, tableContent=null), ArticleFig(id=1207416373031047750, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, label=图2, caption=伏诺拉生双联方案与三联方案的幽门螺杆菌根除率比较

ITT. 意向性分析

, figureFileSmall=9BguXX4TNRAFy+n+ZQZ5Yw==, figureFileBig=8ZFR7VjiCved1jbOtzKFHw==, tableContent=null), ArticleFig(id=1207416374213841478, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=EN, label=Tab. 1, caption=

Studies on eradicationof Helicobacter pylori by vonoprazan regimen

, figureFileSmall=null, figureFileBig=null, tableContent=

文献(年份)	研究设计	根除方案	伏诺拉生/PPIs及剂量	抗生素和铋剂及其剂量	疗程(d)	患者数(例)	Hp根除率[%(例)]	总体不良反应发生率(%)	主要不良反应	有无严重不良反应
Katayama(2016)[14]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	258	90.6 (234/258)	NR	皮疹	NR
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	23	87.0 (20/23)	NR	皮疹	NR
Murakami(2016)[15]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	329	92.6 (300/324)	34.0	腹泻、鼻咽炎、味觉障碍	有(4例)
			兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	321	75.9 (243/320)	41.1	腹泻、鼻咽炎、腹胀有	(2例)
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	50	98.0 (49/50)	30.0	腹泻、鼻咽炎、腹胀有	(2例)
Maruyama(2017)[16]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	72	PP：95.7 (67/70) ITT：95.8 (69/72)	26.3	味觉障碍、腹泻、皮疹	无
			兰索拉唑30 mg，2次/d；或雷贝拉唑20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	69	PP：71.4 (45/63) ITT：69.6 (48/69)	37.7	味觉障碍、腹泻、皮疹	无
Sue(2017)[17]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	55	PP：88.9 (48/54) ITT：87.3 (48/55)	NR	味觉障碍、腹泻、厌食	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	51	PP：86.7 (39/45) ITT：76.5 (39/51)	NR	味觉障碍、腹泻、厌食	无
Ozaki(2018)[18]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	1688	90.8 (1533/1688)	NR	NR	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	71/76	77.5 (55/71)/68.4 (52/76)	NR	NR	无
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	154	86.3 (133/154)	NR	NR	无
Sue(2017)[19]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	623	PP：86.4 (529/612) ITT：84.9 (529/623)	25.0	味觉障碍、厌食、恶心	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	608	PP：79.4 (479/603) ITT：78.8 (479/608)	49.0	味觉障碍、厌食、恶心	无
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	216	PP：82.4 (174/211) ITT：80.5 (174/216)	NR	NR	NR
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	146	PP：82.1 (119/145) ITT：81.5 (119/146)	NR	NR	NR
Saito(2019)[20]	队列研究	三线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	57	PP：93.0 (53/57) ITT：93.0 (53/57)	NR	NR	NR
			艾司奥美拉唑20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	24	PP：56.5 (13/23) ITT：54.2 (13/24)	NR	NR	NR
Sue(2018)[21]	随机对照试验	三线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	33	PP：83.3 (25/30) ITT：75.8 (25/33)	NR	味觉障碍、厌食、恶心	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	30	PP：57.1 (16/28) ITT：53.3 (16/30)	NR	味觉障碍、厌食、恶心	无
Sue(2017)[22]	队列研究	一线方案(青霉素过敏)	伏诺拉生20 mg，2次/d	克拉霉素200或400 mg，2次/d；甲硝唑250 mg，2次/d	7	20	PP：100.0 (20/20) ITT：100.0 (20/20)	NR	恶心、腹痛、腹胀	无
			艾司奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	克拉霉素200或400 mg，2次/d；甲硝唑250 mg，2次/d	7	30	PP：56.5 (16/29) ITT：54.2 (16/30)	NR	味觉障碍、腹泻、烧心	无
Okubo(2020)[23]	队列研究	一线方案(克拉霉素耐药)	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	146	PP：89.4 (42/47) ITT：84.0 (42/50)	11.0	腹泻、烧心	无
Suzuki(2020)[24]	随机对照试验	双联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d	7	168	PP：84.5 (142/163) ITT：87.1 (142/168)	27.4	腹泻、鼻咽炎、腹胀	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	167	PP：90.2 (148/164) ITT：89.2 (149/167)	30.5	腹泻、鼻咽炎、腹胀	无
Gotoda(2020)[25]	队列研究	双联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d	7	60	PP：86.4 (51/59) ITT：85.0 (51/60)	10.0	腹泻、腹胀	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	161	PP：84.0 (132/157) ITT：81.9 (132/161)	19.8	腹泻、稀便	无
Furuta(2020)[26]	队列研究	双联方案	伏诺拉生20 mg，2次/d	阿莫西林500 mg，3次/d	7	56	PP：94.4 (51/54) ITT：92.9 (52/56)	14.3	皮疹、腹泻	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	56	PP：92.7 (51/55) ITT：91.1 (51/56)	25.0	腹泻、腹痛	无
Hirata(2020)[27]	队列研究	10 d三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；利福布汀150 mg，2次/d	10	19	100.0 (19/19)	21.0	腹泻、稀便	NR
Huh(2021)[28]	随机对照试验	14 d含铋四联方案	伏诺拉生20 mg，2次/d	阿莫西林1000 mg，2次/d；克拉霉素500 mg，2次/d；铋剂220 mg，2次/d	14	12	100.0 (12/12)	NR	心悸、腹泻	无
			兰索拉唑30 mg，2次/d	阿莫西林1000 mg，2次/d；克拉霉素500 mg，2次/d；铋剂220 mg，2次/d	14	14	100.0 (14/14)	NR	腹泻、黑便	无
Ono(2017)[29]	队列研究	三联方案(青霉素过敏)	伏诺拉生20 mg，2次/d	克拉霉素200 mg，2次/d；甲硝唑250 mg，2次/d	7	14	PP：92.9 (13/14) ITT：92.9 (13/14)	NR	腹泻、稀便	无
			雷贝拉唑20 mg，2次/d或兰索拉唑30 mg，2次/d	克拉霉素200 mg，2次/d；甲硝唑250 mg，2次/d	7	13	PP：54.6 (6/11) ITT：46.2 (6/13)	NR	腹泻、稀便	无
			伏诺拉生20 mg，2次/d	甲硝唑250 mg，2次/d；西他沙星100 mg，2次/d	7	17	PP：93.8 (15/16) ITT：88.2 (15/17)	NR	腹泻、稀便	无
			雷贝拉唑20 mg，2次/d或兰索拉唑30 mg，2次/d	甲硝唑250 mg，2次/d；西他沙星100 mg，2次/d	7	44	PP：100.0 (44/44) ITT：100.0 (44/44)	NR	腹泻、稀便	无

), ArticleFig(id=1207416374352253516, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1207416367888830837, language=CN, label=表1, caption=

伏诺拉生方案根除Hp的相关研究

, figureFileSmall=null, figureFileBig=null, tableContent=

文献(年份)	研究设计	根除方案	伏诺拉生/PPIs及剂量	抗生素和铋剂及其剂量	疗程(d)	患者数(例)	Hp根除率[%(例)]	总体不良反应发生率(%)	主要不良反应	有无严重不良反应
Katayama(2016)[14]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	258	90.6 (234/258)	NR	皮疹	NR
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	23	87.0 (20/23)	NR	皮疹	NR
Murakami(2016)[15]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	329	92.6 (300/324)	34.0	腹泻、鼻咽炎、味觉障碍	有(4例)
			兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	321	75.9 (243/320)	41.1	腹泻、鼻咽炎、腹胀有	(2例)
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	50	98.0 (49/50)	30.0	腹泻、鼻咽炎、腹胀有	(2例)
Maruyama(2017)[16]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	72	PP：95.7 (67/70) ITT：95.8 (69/72)	26.3	味觉障碍、腹泻、皮疹	无
			兰索拉唑30 mg，2次/d；或雷贝拉唑20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	69	PP：71.4 (45/63) ITT：69.6 (48/69)	37.7	味觉障碍、腹泻、皮疹	无
Sue(2017)[17]	随机对照试验	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	55	PP：88.9 (48/54) ITT：87.3 (48/55)	NR	味觉障碍、腹泻、厌食	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	51	PP：86.7 (39/45) ITT：76.5 (39/51)	NR	味觉障碍、腹泻、厌食	无
Ozaki(2018)[18]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	1688	90.8 (1533/1688)	NR	NR	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	71/76	77.5 (55/71)/68.4 (52/76)	NR	NR	无
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	154	86.3 (133/154)	NR	NR	无
Sue(2017)[19]	队列研究	一线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	623	PP：86.4 (529/612) ITT：84.9 (529/623)	25.0	味觉障碍、厌食、恶心	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200或400 mg，2次/d	7	608	PP：79.4 (479/603) ITT：78.8 (479/608)	49.0	味觉障碍、厌食、恶心	无
		二线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	216	PP：82.4 (174/211) ITT：80.5 (174/216)	NR	NR	NR
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；甲硝唑250 mg，2次/d	7	146	PP：82.1 (119/145) ITT：81.5 (119/146)	NR	NR	NR
Saito(2019)[20]	队列研究	三线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	57	PP：93.0 (53/57) ITT：93.0 (53/57)	NR	NR	NR
			艾司奥美拉唑20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	24	PP：56.5 (13/23) ITT：54.2 (13/24)	NR	NR	NR
Sue(2018)[21]	随机对照试验	三线方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	33	PP：83.3 (25/30) ITT：75.8 (25/33)	NR	味觉障碍、厌食、恶心	无
			艾司奥美拉唑20 mg，2次/d；或雷贝拉唑10 mg，2次/d；或兰索拉唑30 mg，2次/d	阿莫西林750 mg，2次/d；西他沙星100 mg，2次/d	7	30	PP：57.1 (16/28) ITT：53.3 (16/30)	NR	味觉障碍、厌食、恶心	无
Sue(2017)[22]	队列研究	一线方案(青霉素过敏)	伏诺拉生20 mg，2次/d	克拉霉素200或400 mg，2次/d；甲硝唑250 mg，2次/d	7	20	PP：100.0 (20/20) ITT：100.0 (20/20)	NR	恶心、腹痛、腹胀	无
			艾司奥美拉唑20 mg，2次/d；或兰索拉唑30 mg，2次/d	克拉霉素200或400 mg，2次/d；甲硝唑250 mg，2次/d	7	30	PP：56.5 (16/29) ITT：54.2 (16/30)	NR	味觉障碍、腹泻、烧心	无
Okubo(2020)[23]	队列研究	一线方案(克拉霉素耐药)	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	146	PP：89.4 (42/47) ITT：84.0 (42/50)	11.0	腹泻、烧心	无
Suzuki(2020)[24]	随机对照试验	双联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d	7	168	PP：84.5 (142/163) ITT：87.1 (142/168)	27.4	腹泻、鼻咽炎、腹胀	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	167	PP：90.2 (148/164) ITT：89.2 (149/167)	30.5	腹泻、鼻咽炎、腹胀	无
Gotoda(2020)[25]	队列研究	双联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d	7	60	PP：86.4 (51/59) ITT：85.0 (51/60)	10.0	腹泻、腹胀	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	161	PP：84.0 (132/157) ITT：81.9 (132/161)	19.8	腹泻、稀便	无
Furuta(2020)[26]	队列研究	双联方案	伏诺拉生20 mg，2次/d	阿莫西林500 mg，3次/d	7	56	PP：94.4 (51/54) ITT：92.9 (52/56)	14.3	皮疹、腹泻	无
		一线三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；克拉霉素200 mg，2次/d	7	56	PP：92.7 (51/55) ITT：91.1 (51/56)	25.0	腹泻、腹痛	无
Hirata(2020)[27]	队列研究	10 d三联方案	伏诺拉生20 mg，2次/d	阿莫西林750 mg，2次/d；利福布汀150 mg，2次/d	10	19	100.0 (19/19)	21.0	腹泻、稀便	NR
Huh(2021)[28]	随机对照试验	14 d含铋四联方案	伏诺拉生20 mg，2次/d	阿莫西林1000 mg，2次/d；克拉霉素500 mg，2次/d；铋剂220 mg，2次/d	14	12	100.0 (12/12)	NR	心悸、腹泻	无
			兰索拉唑30 mg，2次/d	阿莫西林1000 mg，2次/d；克拉霉素500 mg，2次/d；铋剂220 mg，2次/d	14	14	100.0 (14/14)	NR	腹泻、黑便	无
Ono(2017)[29]	队列研究	三联方案(青霉素过敏)	伏诺拉生20 mg，2次/d	克拉霉素200 mg，2次/d；甲硝唑250 mg，2次/d	7	14	PP：92.9 (13/14) ITT：92.9 (13/14)	NR	腹泻、稀便	无
			雷贝拉唑20 mg，2次/d或兰索拉唑30 mg，2次/d	克拉霉素200 mg，2次/d；甲硝唑250 mg，2次/d	7	13	PP：54.6 (6/11) ITT：46.2 (6/13)	NR	腹泻、稀便	无
			伏诺拉生20 mg，2次/d	甲硝唑250 mg，2次/d；西他沙星100 mg，2次/d	7	17	PP：93.8 (15/16) ITT：88.2 (15/17)	NR	腹泻、稀便	无
			雷贝拉唑20 mg，2次/d或兰索拉唑30 mg，2次/d	甲硝唑250 mg，2次/d；西他沙星100 mg，2次/d	7	44	PP：100.0 (44/44) ITT：100.0 (44/44)	NR	腹泻、稀便	无

)], attaches=null, journal=Journal(id=1146441329971666965, delFlag=0, nameCn=解放军医学杂志, nameEn=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, issn=0577-7402, eissn=null, cn=11-1056/R, coden=null, periodic=0, language=CN, oaType=是, ccby=CC BY-NC-ND, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=6srot5PcoYX30Oa4xeTmeg==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1751262512917, updatedTime=1761735725513, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=M, firstLetterEn=M, subjectCode=Life Sciences, subjectName=Life Sciences, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=6srot5PcoYX30Oa4xeTmeg==, picEn=ELwBh5xqrSTlIs7HmSNt2Q==, jcr=null, cjcr=null, exts=[JournalExt(id=1190369167564968109, language=CN, name=解放军医学杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725537, updatedTime=1761735725537, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1190369167615299758, language=EN, name=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725549, updatedTime=1761735725549, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189873630562394117, websiteList=[Website(id=1189873845923287108, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN, language=CN, createTime=1761617631655, createBy=18614031015, updateTime=1761622010471, updateBy=18614031015, name=解放军医学杂志-中文, tplId=1146099689490845704, title=解放军医学杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924939378520839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=articleTextType, value=kx, createTime=1761629813284, updateTime=1761629813284, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939353355012, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=banner, value=null, createTime=1761629813278, updateTime=1761629813278, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939399492362, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=grayFlag, value=0, createTime=1761629813289, updateTime=1761629813289, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939344966403, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629813276, updateTime=1761629813276, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939412075276, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=minRunFlag, value=0, createTime=1761629813292, updateTime=1761629813292, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939374326534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic, createTime=1761629813283, updateTime=1761629813283, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939407880971, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=silenceFlag, value=0, createTime=1761629813291, updateTime=1761629813291, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939361743621, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761629813280, updateTime=1761629813280, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939386909448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeColor, value=null, createTime=1761629813286, updateTime=1761629813286, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939395298057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeStyle, value=null, createTime=1761629813288, updateTime=1761629813288, creator=18614031015, updator=18614031015)]), Website(id=1189873846057504839, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN, language=EN, createTime=1761617631687, createBy=18614031015, updateTime=1761622030030, updateBy=18614031015, name=解放军医学杂志-英文, tplId=1146101810881728533, title=Medical Journal of Chinese People’s Liberation Army, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924968168223505, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=articleTextType, value=kx, createTime=1761629820148, updateTime=1761629820148, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968147251982, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=banner, value=null, createTime=1761629820143, updateTime=1761629820143, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968185000724, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=grayFlag, value=0, createTime=1761629820152, updateTime=1761629820152, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968138863373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629820141, updateTime=1761629820141, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968197583638, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=minRunFlag, value=0, createTime=1761629820155, updateTime=1761629820155, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968159834896, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic, createTime=1761629820146, updateTime=1761629820146, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968193389333, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=silenceFlag, value=0, createTime=1761629820154, updateTime=1761629820154, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968155640591, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761629820145, updateTime=1761629820145, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968172417810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeColor, value=null, createTime=1761629820149, updateTime=1761629820149, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968180806419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeStyle, value=null, createTime=1761629820151, updateTime=1761629820151, creator=18614031015, updator=18614031015)])], journalTitle=解放军医学杂志, weixinUrl=null, journalUrl=http://zh.jfjyxzz.org.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Medical Journal of Chinese People’s Liberation Army, journalPhotoCn=6srot5PcoYX30Oa4xeTmeg==, journalPhotoEn=ELwBh5xqrSTlIs7HmSNt2Q==, journalFirstLetter=M, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/10.11855/j.issn.0577-7402.2022.09.0947, detailUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/10.11855/j.issn.0577-7402.2022.09.0947, pdfUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/PDF/10.11855/j.issn.0577-7402.2022.09.0947, pdfUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/PDF/10.11855/j.issn.0577-7402.2022.09.0947, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)